SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing heightened community engagement as speculators debate its potential for a sharp technical reversal, fueled by ongoing discussions regarding its utility, ecosystem developments like ApeChain, and speculative comparisons to past market cycles. While some traders are actively hunting for entry points amid high volatility, others remain cautious, debating whether recent price fluctuations represent a bottoming process or continued downward pressure.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending as investors weigh strong infrastructure-driven earnings and upward guidance against significant volatility and skepticism regarding the sustainability of its rapid price rally. Community discourse is sharply divided, with some traders focused on potential short-squeeze dynamics and the company's role in AI data center growth, while others express concerns over valuation, lack of profitability, and the risk of a sharp correction.

Index Coop is a decentralized autonomous organization (DAO) that builds structured DeFi products and strategy tokens. Index Coop offers a suite of sector index products, leverage and inverse products, and yield-generating products. The product suite runs on Set Protocol, an audited, self-custodial DeFi tool that allows for the creation and management of Ethereum-based (or ERC-20) tokens. Changes to the DAO are voted on by the owners of a governance token called INDEX and then implemented by a team of developers. INDEX holders wield voting power on a 1:1 basis, meaning one token equals one vote.

Index Cooperative

Index Cooperative is seeing renewed community interest as traders highlight its low circulating supply and potential for explosive price moves during DeFi market expansions. Supporters are actively discussing the token's governance role, its leverage-focused product suite, and the possibility of a breakout similar to previous cycles.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors await a critical Phase 3 data readout for its hereditary angioedema therapy, with high short interest fueling anticipation for a potential short squeeze. The community is actively discussing the stock's significant price volatility and the potential impact of this binary event on the company's long-term position in the gene-editing sector.

Chip

Chip is experiencing high volatility following recent listings on major trading platforms, sparking a fierce debate among the community regarding whether it represents a legitimate AI-infrastructure utility or a classic pump-and-dump scheme. Investors are actively watching support levels and discussing the potential for a short squeeze as the token gains traction on social feeds.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is trending following a Barron's report identifying it as a prime candidate for a potential short squeeze, sparking intense discussion among retail traders about a massive insider share purchase by the CEO. Investors are actively debating the timing of a rally, with community sentiment split between those anticipating a major catalystsuch as a potential AI partnershipand those frustrated by the stock's recent volatility and underperformance compared to the broader software sector.

Harvest Portfolios Group Inc - Harvest Canadian High Income Shares ETF

Harvest Canadian High Income Shares ETF

Investors are closely monitoring Harvest Canadian High Income Shares due to recent distribution adjustments and content creator analysis highlighting the fund's role in passive income strategies. Discussions across social platforms center on the portfolio's stability and its competitive positioning within the broader Canadian covered call ETF sector.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors aggressively trade around significant volume and high short interest, with the community actively speculating that an imminent commercial deal or partnership news is on the horizon. Despite persistent skepticism regarding the lack of recurring revenue, sentiment is currently buoyed by hopeful 'dot-connecting' related to the firm's advanced semiconductor material integration and anticipated industry collaborations.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is currently trending as investors focus on the upcoming topline secondary endpoint data from its COMPANION-002 Phase 2/3 study, which is a critical binary event for the company's lead asset in the biliary tract cancer space. Community sentiment remains highly active with discussions centered on potential stock price catalysts and technical indicators, though some market participants are expressing caution regarding clinical trial uncertainties and the speculative nature of biotech momentum plays.

"KISHU INU was created in April 2021 with the goal of being a decentralized meme project with true purpose.  KISHU’s mission is to bring popular cryptocurrency concepts to the mainstream. Unlike older, comparable projects, KISHU introduces holders to next-gen concepts such as participation rewards, NFTs, decentralized exchanges, and more.  Within the first month of its launch, KISHU made history by surpassing a $2 billion market cap and over 100,000 holders. This was an unprecedented milestone for a project of its kind, and proved the world’s belief in the project."

KISHU INU

KISHU INU is trending as retail investors speculate on a potential rally, driven by long-term holders debating the coin's utility, burn mechanisms, and comparisons to previous meme coin market cycles. The community remains polarized, with some accumulating positions in anticipation of a new market cycle, while others warn of its historical performance and ongoing liquidity concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics (NASDAQ:SMMT)  Shares Down 6.2%   - Time to Sell?

Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.2% - Should You Sell...

Investors Buy Large Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics PLC (NASDAQ:SMMT - Get Free Report) saw unusually large options trading activity on Wednesday. Investors purchased 16,625 call options on the stock. This represents an increase of...

Summit Therapeutics (NASDAQ:SMMT) Sees Strong Trading Volume - Here's Why

Summit Therapeutics (NASDAQ:SMMT) Sees Large Volume Increase - What's Next...

Notable Thursday Option Activity: SMMT, AEHR, MDB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Summit Therapeutics Inc (Symbol: SMMT), where a total volume of 18,465 contracts has been traded thus far today, a contract volume which is representative of app...

Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.2%  - Still a Buy?

Summit Therapeutics (NASDAQ:SMMT) Shares Up 8.2% - Here's Why...

SMMT Stock Up 24% in Three Months: Here's What You Need to Know

Summit Therapeutics stock jumps as FDA accepts ivonescimab BLA. Strong trial data and partnerships boost confidence in its cancer therapy pipeline.

Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst

Stifel initiates coverage on Summit Therapeutics (SMMT) with a Buy rating and $45 price target, citing ivonescimab's $200B market potential.read more...

Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Summit Therapeutics in a research report on Wednesday. They issued a "buy" rating and a $45.00 target price on the stock...

Tudor Investment Corp ET AL Takes $7.17 Million Position in Summit Therapeutics PLC $SMMT

Tudor Investment Corp ET AL purchased a new stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 347,241 shares of the company's stock, valu...

Aberdeen Group plc Reduces Stake in Summit Therapeutics PLC $SMMT

Aberdeen Group plc lowered its stake in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 18.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the...

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.27	--	--	N/A
Q4 '25	-$0.09	-$0.29	-233.67%	MISSED
Q3 '25	-$0.18	-$0.31	-76.36%	MISSED
Q2 '25	-$0.09	-$0.76	-736.88%	MISSED
Q1 '25	-$0.09	-$0.09	3.25%	BEAT

SMMT
Summit Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest SMMT News

SMMTSummit Therapeutics Inc